10x Genomics, Inc. announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2025.
The company reported revenue of approximately $166.0 million for the fourth quarter and $642.8 million for the full year 2025.
The financial results included breakdowns of revenue from instruments, consumables, and services.
Revenue Growth
Revenue for the fourth quarter showed 11% sequential growth and 1% year-over-year growth, while full year revenue decreased by 2% excluding patent litigation settlements.
Product Revenue
Instruments revenue saw fluctuations with significant growth in consumables and services revenue in 2025.
Operational Performance
10x Genomics emphasized the importance of strong partnerships, product roadmap progress, and tight operational discipline in maintaining a robust balance sheet.
Financial Position
The company reported having cash, cash equivalents, and marketable securities totaling approximately $520 million as of December 31, 2025.
Future Outlook
CEO Serge Saxonov expressed confidence in the company's future impact and positioning for continued success.
- The reported financial results demonstrate the company's ability to navigate challenges and maintain growth momentum in a competitive environment.
- 10x Genomics' product mix and strategic focus on partnerships and operational efficiency contributed to its financial performance in 2025.
10x Genomics' preliminary financial results for the fourth quarter and full year 2025 reflect a mixed performance with revenue fluctuations and operational strength. The company's CEO remains optimistic about future prospects and growth opportunities.